NCT01878890View on ClinicalTrials.gov

Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 5, 2011

Primary Completion Date

September 16, 2014

Study Completion Date

December 31, 2016

Conditions
Solid TumorsNon-Hodgkin's Lymphoma
Interventions
DRUG

Efavirenz 600mg

Efavirenz 600 mg (oral daily intake)

DRUG

Efavirenz 1200 mg

Efavirenz 1200mg (oral daily intake)

DRUG

Efavirenz 1800 mg

Efavirenz 1800mg (oral daily intake)

DRUG

Efavirenz 2200 mg

Efavirenz 2200mg (oral daily intake)

Trial Locations (1)

33076

Institut Bergonié, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié
All Listed Sponsors
lead

Institut Bergonié

OTHER